Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2008, for RXi Pharmaceuticals Corporation (RXi). RXi is a discovery-stage biopharmaceutical company focused on developing proprietary therapeutics based on RNA interference (RNAi) for neurodegenerative diseases, metabolic diseases, and oncology. The company was formed in 2006 by CytRx Corporation and four RNAi researchers, including Nobel laureate Dr. Craig Mello. RXi is classified as a development stage company and has generated no revenue since inception.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 | Cumulative (Inception to Mar 31, 2008) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(2,646,000) | $(1,412,000) | $(23,677,000) |
| Operating Loss | $(2,713,000) | $(1,412,000) | $(24,192,000) |
| Research & Development Expense | $1,088,000 | $824,000 | $16,376,000 |
| General & Administrative Expense | $1,625,000 | $588,000 | $7,816,000 |
| Cash and Cash Equivalents (End of Period) | $9,857,000 | $3,000 | $9,857,000 |
| Short-term Investments | $0 | $9,952,000 | $0 |
| Total Assets | $10,580,000 | $12,147,000 | $10,580,000 |
| Total Liabilities | $1,774,000 | $1,324,000 | $1,774,000 |
| Stockholders' Equity | $8,806,000 | $10,823,000 | $8,806,000 |
Note: All financial figures are in thousands, except per share data.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately 87% to $2.65 million from $1.41 million in the prior year quarter, driven by higher operating expenses.
- Expense Growth:
- R&D Expenses: Increased 32% to $1.09 million due to higher staff and supply costs, partially offset by lower non-employee stock-based compensation.
- G&A Expenses: Increased 176% to $1.63 million. This was primarily due to higher staff-related costs (including $423,000 in stock option compensation) and costs associated with operating as a public company (legal, printing, investor relations).
- Liquidity Shift: Cash and cash equivalents increased significantly to $9.86 million from $1.76 million at year-end 2007. This was driven by the maturity of $9.78 million in short-term investments (U.S. Treasury Bills) during the quarter. Short-term investments were fully liquidated by March 31, 2008.
- Interest Income: The company recorded $75,000 in interest income, compared to none in the prior year, resulting from interest earned on cash and cash equivalents.
Guidance, Outlook, and Risks
- Capital Adequacy: Management believes current cash and cash equivalents ($9.86 million) are sufficient to fund planned operations through the first quarter of 2009.
- Future Expenditures: The company expects to expend approximately $4.6 million on R&D and $2.9 million on G&A through Q1 2009.
- Financing Needs: RXi expects to incur significant and increasing operating losses. Future operations depend on obtaining third-party financing. There are currently no commitments for additional funding. Failure to secure capital could force the company to scale back or terminate operations.
- Revenue Outlook: No revenue is expected in the foreseeable future. The company remains in the discovery stage with no products approved for commercialization.
- Subsequent Events: In April 2008, the company granted stock options to board members, employees, and consultants, and entered into a $35,000 lease for laboratory equipment.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the $9.86 million cash balance and the projection that it will sustain operations only until Q1 2009.
- Financing Strategy: Confirm the status of any discussions with third-party investors, given the explicit statement that no commitments exist for future funding.
- Expense Trajectory: Monitor the rapid increase in G&A expenses (176% YoY) and assess if this trend is sustainable relative to the cash burn rate.
- Stock-Based Compensation: Review the impact of non-cash stock-based compensation ($629,000 in Q1 2008) on the net loss and future dilution risks.
- Parent Company Relationship: Note the historical reliance on CytRx Corporation for funding and the elimination of indirect cost allocations from CytRx in the current period.